John Huggins to Protein Kinase Inhibitors
This is a "connection" page, showing publications John Huggins has written about Protein Kinase Inhibitors.
Connection Strength
0.357
-
Lung function outcomes in the INPULSIS? trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019 01; 146:42-48.
Score: 0.127
-
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan; 7(1):60-68.
Score: 0.125
-
Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009 Nov; 338(5):414-7.
Score: 0.068
-
Systemic sclerosis with associated interstitial lung disease: management considerations and future directions. Am J Manag Care. 2021 05; 27(7 Suppl):S138-S146.
Score: 0.038